Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results

Rhea-AI Summary

Personalis, Inc. (NASDAQ: PSNL) announced it will release its fourth quarter and full year 2022 financial results on February 23, 2023. A conference call and webcast will be held on the same day at 2:00 p.m. PT to discuss these results along with recent highlights. Interested participants can register in advance to access the live call. The company focuses on advanced cancer genomics, providing insights on approximately 20,000 human genes through its Personalis NeXT Platform. The laboratory is certified and accredited for its clinical accuracy and efficiency. More updates will be available after the conclusion of the call.

Positive

• Scheduled financial results release for Q4 and full year 2022 shows readiness for investor engagement.
• Focus on advanced genomics positions the company for growth in precision oncology market.

Negative

• None.

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis, Inc.

Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and News Center, and follow Personalis on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005650/en/

Investor Relations Contact:

Caroline Corner

investors@personalis.com

415-202-5678

Media Contact:

Jennifer Temple

pr@personalis.com

www.personalis.com

650-752-1300

Source: Personalis, Inc.

FAQ

When will Personalis report its Q4 and full year 2022 financial results?

Personalis will report its Q4 and full year 2022 financial results on February 23, 2023.

What time will the Personalis conference call take place?

The Personalis conference call will take place at 2:00 p.m. Pacific Time on February 23, 2023.

How can I access the Personalis conference call?

You can access the Personalis conference call by registering in advance via the link provided in their press release.

What is the focus of Personalis' business?

Personalis focuses on advanced cancer genomics, providing insights for precision oncology therapies and diagnostics.

What is the Personalis NeXT Platform?

The Personalis NeXT Platform is designed to analyze all approximately 20,000 human genes from a single sample for cancer sequencing.